Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst

Key Points

• HC Wainwright raised Cardiol Therapeutics’ Q3 2026 EPS estimate to a loss of $0.06 per share from a previous estimate of $0.08, while maintaining a “Buy” rating.
• Analyst sentiment is mixed: two analysts rate the stock a “Buy” and one rates it a “Sell,” resulting in a consensus “Hold” rating and an $8.50 price target.
• Cardiol reported a quarterly loss of $0.04 per share, beating the $0.09 consensus loss estimate. The stock opened at $1.80, near its 12-month high of $1.82, while institutional investors own 12.49% of shares.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright upped their Q3 2026 earnings estimates for shares of Cardiol Therapeutics in a report issued on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.06) for the quarter, up from their previous forecast of ($0.08). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Cardiol Therapeutics' Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at $0.29 EPS, FY2029 earnings at $0.61 EPS and FY2030 earnings at $1.25 EPS.

Several other brokerages have also issued reports on CRDL. Wall Street Zen upgraded Cardiol Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Cardiol Therapeutics in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.50.

Cardiol Therapeutics Price Performance

CRDL stock opened at $1.80 on Monday. Cardiol Therapeutics has a twelve month low of $0.88 and a twelve month high of $1.82. The company has a market cap of $208.60 million, a PE ratio of -7.20 and a beta of 0.72. The business's 50-day simple moving average is $1.18 and its 200 day simple moving average is $1.18.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.05.

Hedge Funds Weigh In On Cardiol Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in Cardiol Therapeutics by 136.2% in the second quarter. Bank of America Corp DE now owns 26,455 shares of the company's stock valued at $36,000 after acquiring an additional 15,255 shares during the period. Two Sigma Investments LP acquired a new stake in Cardiol Therapeutics during the third quarter valued at approximately $249,000. Virtu Financial LLC acquired a new stake in Cardiol Therapeutics during the third quarter valued at approximately $154,000. Citadel Advisors LLC grew its stake in shares of Cardiol Therapeutics by 1,132.6% in the 3rd quarter. Citadel Advisors LLC now owns 463,462 shares of the company's stock valued at $496,000 after purchasing an additional 425,862 shares during the period. Finally, Susquehanna International Group LLP grew its stake in shares of Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company's stock valued at $100,000 after purchasing an additional 73,375 shares during the period. 12.49% of the stock is owned by institutional investors.

About Cardiol Therapeutics

Cardiol Therapeutics Inc NASDAQ: CRDL is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company's lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source